Despite Prilosec OTC Weakness, P&G Grows With Price Hikes, Cost Cuts

Procter & Gamble's Prilosec OTC business felt the heat of private-label competition during the firm's latest quarter, the first full period since the brand lost market exclusivity as an OTC proton pump inhibitor